Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Withdrawn 1Terminated 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Triple Negative Breast Neoplasms 3Pancreatic Neoplasms 2Colorectal Neoplasms 2Squamous Cell Carcinoma of Head and Neck 1Melanoma 1Carcinoma, Transitional Cell 1Carcinoma, Squamous Cell 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Medullary 1

Interventions

Gemcitabine 205130-nm albumin-bound paclitaxel 84Albumin-Bound Paclitaxel 57pembrolizumab 43Fluorouracil 41Leucovorin 34Oxaliplatin 33Capecitabine 25Nivolumab 22Irinotecan 19Bevacizumab 17Paclitaxel 16Cyclophosphamide 15Cetuximab 15Taxes 13Erlotinib Hydrochloride 13Drug Therapy 13Carboplatin 12irinotecan sucrosofate 11Injections 10Cisplatin 9fludarabine 8ALT-803 8spartalizumab 7olaparib 7avelumab 7Pemetrexed 7Docetaxel 7ruxolitinib 6TH 302 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Pancreatic Neoplasms × yeast-CEA vaccine × Clear all
NCT03563144 2025-02-21

QUILT-3.088: NANT Pancreatic Cancer Vaccine

ImmunityBio, Inc.

Phase 2 Withdrawn
Gastrointestinal

Pancreatic Neoplasms

NCT03586869 2024-08-27

QUILT-3.080: NANT Pancreatic Cancer Vaccine

ImmunityBio, Inc.

Phase 1/2 Terminated
3 enrolled 13 charts
Gastrointestinal

Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡